- Report
- October 2024
- 186 Pages
Global
From €3235EUR$3,545USD£2,759GBP
€3595EUR$3,939USD£3,065GBP
- Report
- April 2025
- 175 Pages
Global
From €4098EUR$4,490USD£3,494GBP
- Report
- August 2024
- 147 Pages
Global
From €2737EUR$2,999USD£2,334GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3422EUR$3,750USD£2,918GBP
- Report
- November 2021
- 295 Pages
Global
From €2510EUR$2,750USD£2,140GBP
€5019EUR$5,500USD£4,280GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1141EUR$1,250USD£973GBP
- Report
- April 2023
- 147 Pages
Global
From €4517EUR$4,949USD£3,851GBP
- Report
- April 2023
- 120 Pages
Global
From €4335EUR$4,750USD£3,696GBP
- Report
- October 2024
- 72 Pages
Global
From €3500EUR$4,108USD£3,089GBP
- Report
- April 2022
- 210 Pages
Global
From €2208EUR$2,419USD£1,883GBP
€3154EUR$3,456USD£2,689GBP
Micafungin is an antifungal drug used to treat a variety of fungal infections. It is a member of the echinocandin class of antifungal drugs, which are used to treat serious fungal infections caused by Candida species. Micafungin is used to treat candidemia, a bloodstream infection caused by Candida, as well as other forms of invasive candidiasis, such as esophageal candidiasis and peritonitis. It is also used to prevent Candida infections in patients undergoing bone marrow transplantation.
Micafungin is a key player in the infectious diseases drugs market, as it is used to treat a variety of fungal infections. It is an important drug for treating serious fungal infections, and is used in combination with other antifungal drugs to treat more severe infections.
Some companies in the Micafungin market include Astellas Pharma, Pfizer, Merck, and Novartis. Show Less Read more
